Delving into the Latest Updates on LMB-2 with Synapse

Overview

Basic Info

Drug Type

Antibody toxin conjugate

Synonyms

LMB-2A

Target

IL2RA

Action

inhibitors

Mechanism

IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]

Active Indication-

Inactive Indication

Adult T-Cell Leukemia-LymphomaCD25 Positive B-Cell Chronic Lymphocytic LeukemiaCutaneous T-Cell Lymphoma+ [5]

Originator Organization

National Cancer Institute

Active Organization-

Inactive Organization

National Cancer InstituteNational Institutes of Health Clinical Center

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

BACKGROUND:
* Cluster of differentiation 25 (CD25) (p55, Tac or interleukin 2 receptor (IL2R) alpha) is strongly expressed in virtually 100% of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTLV-1) related malignancy responding poorly to chemotherapy.
* In ATL, the humanized anti-CD25 monoclonal antibody (Mab) daclizumab produced 13-14% responses, and the anti-CD52 Mab Alemtuzumab (Campath-1H) produced response lasting greater than 2 months in 30% of 23 patients.
* LMB-2 is an anti-CD25 recombinant immunotoxin containing variable domains of murine MAb anti-Tac and truncated Pseudomonas exotoxin.
* In a phase I trial at National Cancer Institute (NCI), the maximum tolerated dose (MTD) of LMB-2 was 40 microg/Kg intravenous (IV) given every other day for 3 doses (every other day (QOD) times 3). LMB-2 induced greater than 90% tumor reduction rapidly in all 3 ATL patients on protocol, but achieved only 1 partial response due to rapid tumor progression and/or immunogenicity.
* In preclinical models, response from recombinant immunotoxins is limited by high concentrations of soluble receptor in the blood and especially in the interstitial space of the tumor. Synergism was observed with chemotherapy and immunotoxins, possibly due to reduction of soluble receptor in tumor interstitium.
OBJECTIVES:
-To determine, in nonrandomized fashion, if after verifying its safety, fludarabine and cyclophosphamide (FC) prior to LMB2 for ATL can result in low immunogenicity and a rate of major response lasting greater than 2 months, which may be an improvement over that demonstrated previously from Alemtuzumab (CAMPATH).
Secondary objectives:
* To determine the effect of 1 cycle of FC alone in ATL.
* To examine progression-free and overall survival in ATL after FC/LMB-2.
* Evaluate pharmacokinetics, toxicity, and monitor soluble CD25 and other tumor marker levels in the serum.
* To study the effects of LMB-2 plus FC on normal B- and T-cell subsets by fluorescence-activated cell sorting (FACS).
ELIGIBILITY:
* CD25 plus ATL, untreated or with prior therapy
* Eastern Cooperative Oncology Group (ECOG) 0-2, absolute neutrophil count (ANC), platelets and albumin at least 1000, 75,000, and 3.0.
DESIGN:
* Fludarabine 25 mg/m(2) IV days 1-3
* Cyclophosphamide 250 mg/m(2) IV days 1-3
* LMB-2 30-40 micro g/Kg IV days 3, 5 and 7.
* LMB-2 dose: Begin with 30 microg/Kg times 3. Escalate to 40 microg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 microg/Kg. Continue at 40 microg/Kg if 0-1 of 6 have DLT at 40 microg/Kg.
* Administer cycle 1 with FC alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
* Accrual goals: 29-37 patients, which includes 4 replacements....

Start Date31 Oct 2008

Sponsor / Collaborator

National Cancer Institute

NCT00389506

/ WithdrawnNot ApplicableIIT

A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. LMB-2 immunotoxin can find cancer cells and kill them without harming normal cells. Giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin works in treating patients with Hodgkin's lymphoma.

Start Date01 Sep 2006

Sponsor / Collaborator

National Institutes of Health Clinical Center

[+1]

NCT00321555

/ CompletedPhase 2IIT

A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia

Background:
* About 80% of patients with hairy cell leukemia (HCL) have tumor cells that have a protein on their surface called cluster of differentiation 25 (CD25).
* The experimental drug LMB-2 is a recombinant immunotoxin that has been shown to kill leukemia and lymphoma cells with the CD25 protein. (A recombinant immunotoxin is a genetically engineered drug that has two parts - a protein that binds or targets a cancer cell, and a toxin that kills the cancer cell to which it binds.)
Objectives:
* To evaluate the safety and effectiveness of LMB-2 in patients with HCL whose cancer cells contain the CD25 protein.
* To evaluate the effects of LMB-2 on the immune system, determine how the drug is metabolized by the body and examine its side effects.
Eligibility:
-Adults with hairy cell leukemia whose tumor cells have CD25 on their surface
Design:
* Up to 27 patients may be included in the study.
* Patients receive an infusion of LMB-2 through a vein every other day for three doses (days 1, 3, 5), constituting one treatment cycle.
* Patients may receive up to six treatment cycles every 4 weeks unless their cancer worsens or they develop unacceptable side effects.
* Blood is drawn weekly for various tests.
* Before each cycle and in follow-up visits, disease status is evaluated with a physical examination, blood tests, chest x-ray and electrocardiogram.
* Before the first cycle, patients may have a computed tomography (CT) scan, echocardiogram (heart ultrasound test) and bone marrow biopsy. With the patient's permission, these tests may be repeated before other cycles also.

Start Date02 May 2006

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with LMB-2

Login to view more data

100 Translational Medicine associated with LMB-2

Login to view more data

100 Patents (Medical) associated with LMB-2

Login to view more data

28

Literatures (Medical) associated with LMB-2

31 Jul 2025·PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

A novel glomerulopathy model demonstrates renal counterbalance via local angiotensin II regulation

Article

Author: KIM, Jun-Dal ; NAGATA, Michio ; MATSUSAKA, Taiji ; SAKAMOTO, Kazuo ; KAWANISHI, Kunio ; TABARA, Saori ; FUKAMIZU, Akiyoshi ; MUROI, Shin-ichi ; KOIZUMI, Masahiro

Renal counterbalance, involving compensatory hypertrophy of the healthy kidney and atrophy of the injured one, remains incompletely understood, particularly at the glomerular level. In this study, we employed NEP25 mice, which selectively express human CD25 in podocytes, enabling precise induction of unilateral podocyte injury through the administration of LMB2, a CD25-targeted immunotoxin. Using a two-kidney, one-nephropathy (2K1N) model, we demonstrated that asymmetric changes in renal blood flow and proteinuria, with histological and transcriptomic analyses uncovering distinct pathological and molecular features between the injured and contralateral healthy kidneys. Notably, an imbalance in intrarenal angiotensin (Ang) II levels was observed, and angiotensin-converting enzyme inhibition ameliorated the glomerular damage and restored perfusion. These findings indicate that local Ang II dysregulation is a key factor in renal counterbalance. Our study provides the first glomerulopathy-based experimental platform to dissect asymmetric renal adaptation, offering fundamental insight into the homeostatic mechanisms of renal function in health and disease.

01 Sep 2019·Hypertension (Dallas, Tex. : 1979)Q1 · MEDICINE

Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner

Q1 · MEDICINE

Article

Author: Yanagita, Motoko ; Fujita, Toshiro ; Saito, Akihiko ; Ueda, Kohei ; Pastan, Ira ; Nishiyama, Akira ; Fukagawa, Masafumi ; Niimura, Fumio ; Matsusaka, Taiji ; Koizumi, Masahiro

We have previously shown that podocyte injury increases the glomerular filtration of liver-derived Agt (angiotensinogen) and the generation of intrarenal Ang II (angiotensin II) and that the filtered Agt is reabsorbed by proximal tubules in a manner dependent on megalin. In the present study, we aimed to study the role of megalin in the generation of renal Ang II and sodium handling during nephrotic syndrome. We generated proximal tubule-specific megalin KO (knockout) mice and crossed these animals with NEP25 mice, in which podocyte-specific injury can be induced by injection of the immunotoxin LMB2. Without podocyte injury, renal Agt staining was markedly diminished and urinary Agt increased in KO mice. However, renal Ang II was similar between KO and control mice on average: 117 (95% CI, 101–134) versus 101 (95% CI, 68–133) fmol/g tissue. We next tested the effect of megalin KO on intrarenal Ang II generation with podocyte injury. Control NEP25 mice showed markedly increased renal Agt staining and renal Ang II levels: 450 (336–565) fmol/g tissue. Megalin KO/NEP25 mice showed markedly diminished Agt reabsorption and attenuated renal Ang II: 199 (156–242) fmol/g tissue ( P <0.001). Compared with control NEP25 mice, megalin KO/NEP25 mice excreted 5-fold more sodium in the urine. Western blot analysis showed that megalin KO decreased NHE3 and the cleaved α and γ forms of Epithelial Na Channel. These data indicate that Agt reabsorbed by proximal tubules via megalin in nephrotic syndrome is converted to Ang II, which may contribute to sodium retention and edema formation by activating NHE3 and Epithelial Na Channel.

01 Jul 2018·Molecular cancer therapeuticsQ2 · MEDICINE

Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

Q2 · MEDICINE

Article

Author: Jang, Youjin ; Pastan, Ira ; Lee, Fred ; Kaplan, Gilad ; Mazor, Ronit ; Leshem, Yasmin

Abstract:

Tac (CD25) is expressed on multiple hematologic malignancies and is a target for cancer therapies. LMB-2 is an extremely active anti-Tac recombinant immunotoxin composed of an Fv that binds to Tac and a 38-kDa fragment of Pseudomonas exotoxin A (PE38). Although LMB-2 has shown high cytotoxicity toward Tac-expressing cancer cells in clinical trials, its efficacy was hampered by the formation of anti-drug antibodies against the immunogenic bacterial toxin and by dose-limiting off-target toxicity. To reduce toxin immunogenicity and nonspecific toxicity, we introduced six point mutations into domain III that were previously shown to reduce T-cell immunogenicity and deleted domain II from the toxin, leaving only the 11aa furin cleavage site, which is required for cytotoxic activity. Although this strategy has been successfully implemented for mesothelin and CD22-targeting immunotoxins, we found that removal of domain II significantly lowered the cytotoxic activity of anti-Tac immunotoxins. To restore cytotoxic activity in the absence of PE domain II, we implemented a combined rational design and screening approach to isolate highly active domain II–deleted toxin variants. The domain II–deleted variant with the highest activity contained an engineered disulfide-bridged furin cleavage site designed to mimic its native conformation within domain II. We found that this approach restored 5-fold of the cytotoxic activity and dramatically improved the MTD. Both of these improvements led to significantly increased antitumor efficacy in vivo. We conclude that the next-generation anti-Tac immunotoxin is an improved candidate for targeting Tac-expressing malignancies. Mol Cancer Ther; 17(7); 1486–93. ©2018 AACR.

100 Deals associated with LMB-2

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adult T-Cell Leukemia-Lymphoma	Phase 2	United States	National Cancer Institute	31 Oct 2008
Hairy Cell Leukemia	Phase 2	United States	National Cancer Institute	02 May 2006
Melanoma, Cutaneous Malignant	Phase 2	United States	National Institutes of Health Clinical Center	01 Dec 2005
Metastatic melanoma	Phase 2	United States	National Institutes of Health Clinical Center	01 Dec 2005
Papilloma	Phase 2	United States	National Institutes of Health Clinical Center	01 Dec 2005
Cutaneous T-Cell Lymphoma	Phase 2	United States	National Cancer Institute	30 Apr 2004
CD25 Positive B-Cell Chronic Lymphocytic Leukemia	Phase 2	United States	National Cancer Institute	29 Feb 2004
TdT Positive Acute Lymphoblastic Leukemia	Phase 1	United States	National Cancer Institute	01 Apr 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00321555 (CTgov)	Phase 2	Hairy Cell Leukemia	15	Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin	kqilyuguwm = ptgccmmuss zfqfpbbikr (djpdkljbnf, evwwwrpfql - sqlgbbvfcz) View more	-	05 Apr 2019
NCT00924170 (CTgov)	Phase 1/2	Adult T-Cell Leukemia-Lymphoma	18	LMB-2 (Leukemic Patients Receiving LMB-2 & At Least 25+250 mg/m^2 FC)	xmktsbcrzp = nfaaopggrk wxolxexbhr (kfuslhyrdb, cznqkcmxqc - lvepeojxyx) View more	-	08 Sep 2017
NCT00924170 (CTgov)	Phase 1/2	Adult T-Cell Leukemia-Lymphoma	18	fludarabine cyclophosphamide (FC)+LMB-2 (All Other Patients)	xmktsbcrzp = useetwdrff wxolxexbhr (kfuslhyrdb, fxryrbivjo - grqaorwhsv) View more	-	08 Sep 2017
NCT00077922 (CTgov)	Phase 2	CD25 Positive B-Cell Chronic Lymphocytic Leukemia	15	LMB-2	uygdtfstah = xvgdmvyhgf kqlzatrqba (bpoodaptkt, pknhgztqfd - hdjiedadvj) View more	-	15 Nov 2012
NCT00080535 (CTgov)	Phase 2	Cutaneous T-Cell Lymphoma	10	LMB-2	bvwxqmeuee = qtpmsqvioj wmktiimwhf (ajamvvsywm, hfnapcruwj - cdthzqxiun) View more	-	24 Oct 2012

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data